Abstracts tagged "Vasculitis"

Abstract Number: 0700 • ACR Convergence 2023
A Population-Based Study of Vasculitis Among Farmers and Urban Residents in Alberta
Elaine Yacyshyn, Simran Gulati, Whitney Hung, Don Voaklander and Allyson Jones, University of Alberta, Edmonton, AB, Canada
Background/Purpose: Systemic vasculitis encompasses a group of autoimmune diseases involving inflammation of blood vessels. Although a rare disease, vasculitis can present with life-threatening symptoms which…
Abstract Number: 0827 • ACR Convergence 2023
Development and Initial Validation of a Brief Measure of Uncertainty in Rheumatic Disease
Caleb Bolden¹, Claire Cook¹, Lucy Finkelstein-Fox¹, Xiaoqing Fu¹, Flavia Castelino¹, Hyon K. Choi², Cory Perugino¹, John Stone³, Elyse Park¹, Zachary Wallace⁴ and Daniel Hall¹, ¹Massachusetts General Hospital, Boston, MA, ²Massachusetts General Hospital and Harvard Medical School, Lexington, MA, ³Massachusetts General Hospital Rheumatology Unit, Harvard Medical School, Concord, MA, ⁴Massachusetts General Hospital, Newton, MA
Background/Purpose: Patients with systemic autoimmune rheumatic disease (SARD) are often tasked with monitoring ambiguous and unpredictable physical symptoms on their own. Higher levels of uncertainty…
Abstract Number: 1543 • ACR Convergence 2023
The Association of Frailty with Outcomes in Patients with Vasculitis
Sebastian Sattui¹, John Stadler², Renee Borchin³, Cristina Burroughs³, Christine Yeung⁴, Peter Merkel⁴ and Robert Spiera⁵, ¹University of Pittsburgh, Pittsburgh, PA, ²Vasculitis Foundation, Kansas City, MO, ³University of South Florida, Tampa, FL, ⁴University of Pennsylvania, Philadelphia, PA, ⁵Hosptial for Special Surgery, New York, NY
Background/Purpose: Frailty is associated with poor health outcomes including increased risk of hospitalizations, infections, and fractures. In the baseline survey of the VascStrong study, we…
Abstract Number: 1646 • ACR Convergence 2023
The Real-World Experience of Combined Cranial and Large Vessel FDG-PET/CT in the Investigation of Giant Cell Arteritis
Keren Port¹, Ivan Ho Shon¹, Sally Ayesa¹, Rachel Langford¹, Olivia Bennett¹, Andrew Csillag¹, Stacey Fredericks¹, Luz Palacios-Derflingher², Eva Wegner¹ and Anthony Sammel¹, ¹The Prince of Wales Hospital, Sydney, Australia, ²University of New South Wales, Sydney, Australia
Background/Purpose: GCA is a systemic medium-large vessel vasculitis (M-LVV) involving the cranial arteries, aorta and its major branches. Recent studies have shown that PET/CT including…
Abstract Number: 2394 • ACR Convergence 2023
18f-FDG-PET/CT for Giant Cell Arteritis Detection of Large Vessel Vasculitis: What Should We Take into Consideration? Analytical Study of the Arteser Registry
Paula V. Estrada-Alarcón¹, Marta Domínguez², Rafael Benito Melero-Gonzalez³, Eugenio De Miguel⁴, Maria. T Silva-Diaz⁵, Jesús Alejandro Valero⁶, Ismael González⁷, Julio Sanchez Martin⁸, Javier Narvaez⁹, Eva Galindez-Agirregoikoa¹⁰, javier Mendizábal¹¹, lydia Abasolo¹², Javier Loricera⁸, Alejandro Muñoz¹³, Santos Castañeda¹⁴, Patricia Moya¹⁵, patricia Moran Alvarez¹⁶, Vanesa Navarro¹⁷, Carles Galisteo¹⁸, Ivette Casafont-Solé¹⁹, Jose Andres Roman Ivorra²⁰, TAREK CARLOS SALMAN MONTE²¹, Margarida Rocha²², Carlota Laura Iñiguez²³, Alicia García²⁴, Cristina Campos²⁵, María Alcalde²⁶, Antonio Juan Mas²⁷, Francisco Javier Prado²⁸, Ricardo Blanco²⁹ and On Behalf of ARTESER Working Group³⁰, ¹Hospital de San Juan Despí Moisès Broggi, Barcelona, Spain, ²Sociedad Española de Reumatología, Madrid, Spain, ³CHU Vigo, O Carballino, Spain, ⁴Hospital Universitario La Paz, Madrid, Spain, ⁵Complexo Hospitalario Universitario A Coruña, A Coruña, Spain, ⁶Department of Rheumatology, Hospital Universitario Donostia, San Sebastián, Spain, ⁷Hospital Universitario de León, León, Spain, ⁸Hospital Universitario Marqués de Valdecilla, Santander, Spain, ⁹Hospital Universitario de Bellvitge, Barcelona, Spain, ¹⁰Basurto University Hospital, Bilbao, Spain, ¹¹Complejo Hospitalario de Navarra, Pamplona, Spain, ¹²Hospital Clínico San Carlos, Madrid, Spain, ¹³Hospital universitario Virgen del Rocío, El Viso de Alcor, Spain, ¹⁴Hospital Universitario de la Princesa, Madrid, Spain, ¹⁵Hospital de Santa Creu i Sant Pau, Barcelona, Spain, ¹⁶Hospital Ramón y Cajal, Madrid, Spain, ¹⁷H Moisès Broggi, Sant Joan Despí, Barcelona, Spain, ¹⁸Hospital Universitario Parc Taulí, Sabadell, Spain, ¹⁹Hospital Germans Trias i Pujol, Badalona, Spain, ²⁰Hospital Universitari i Politècnic la Fe, Valencia, Spain, ²¹Hospital del Mar/Parc de Salut Mar-IMIM, Barcelona, Spain, ²²Osakidetza, Bilbo, Spain, ²³Hospital Universitario Lucus Augusti, Lugo, Spain, ²⁴Hospital Universitario de Canarias, Islas Canarias, ²⁵Rheumatology Unit, Hospital General Universitario de Valencia, Valencia, Spain, ²⁶Hospital Severo Ochoa, Madrid, Spain, ²⁷Hospital Universitario Son Llàtzer, Mallorca, Spain, ²⁸Research department Hospital Infantil de México Federico Gómez, Mexico City, Mexico, ²⁹Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain, ³⁰SER, Spain
Background/Purpose: Imaging studies in patients with giant cell arteritis (GCA) and suspected large vessel vasculitis (LVV) are sensitive, increasingly available, and less aggressive than temporal…
Abstract Number: 2418 • ACR Convergence 2023
Effectiveness of Dose Spacing with Tocilizumab in Giant Cell Arteritis Treatment
Sharon Cowley¹, Colm Kirby², Patricia Harkins³, Richard Conway⁴, Grainne Murphy⁵ and David Kane⁶, ¹Tallaght University Hospital, Dublin, Dublin, Ireland, ²Tallaght University Hospital, Dublin, Ireland, ³St James's Hospital, Dublin, Ireland, ⁴Trinity College Dublin, Dublin, Ireland, ⁵Cork University Hospital, Cork, Ireland, ⁶Tallaght University Hospital & Trinity College Dublin, Dublin, Ireland
Background/Purpose: The only steroid sparing agent approved for treatment of Giant Cell Arteritis (GCA) is the anti-interleukin-6 receptor antagonist tocilizumab. There remains uncertainty regarding treatment…
Abstract Number: 2601 • ACR Convergence 2023
Identification of Giant Cell Arteritis Using Plasma Proteome Profiles Integrated with Machine Learning
kevin cunningham¹, Jaeyun Sung², Benjamin Hur², VINOD GUPTA², Matthew Koster², Cornelia M. Weyand³, David Cuthbertson⁴, Nader Khalidi⁵, Curry Koening⁶, Carol Langford⁷, Carol McAlear⁸, Paul Monach⁹, Larry Moreland¹⁰, Christian Pagnoux¹¹, Rennie Rhee⁸, Philip Seo¹², Peter Merkel⁸ and Kenneth Warrington², ¹University of Minnesota, Minneapolis, MN, ²Mayo Clinic, Rochester, MN, ³Mayo Clinic School of Medicine and Stanford University, Rochester, MN, ⁴University of South Florida, Tampa, FL, ⁵McMaster University, Hamilton, ON, Canada, ⁶University of Texas Dell Medical School, Austin, TX, ⁷Cleveland Clinic, Cleveland, OH, ⁸University of Pennsylvania, Philadelphia, PA, ⁹VA Boston Healthcare System, Boston, MA, ¹⁰University of Colorado, Denver, CO, ¹¹Mount Sinai Hospital, Toronto, ON, Canada, ¹²Johns Hopkins University, Baltimore, MD
Background/Purpose: The availability of diagnostic laboratory tests and specific biomarkers of disease activity for giant cell arteritis (GCA) remains an area of unmet need. The…
Abstract Number: 031 • 2023 Pediatric Rheumatology Symposium
Multisystem Inflammatory Syndrome in Children Phenotypes Vary Between SARS-CoV-2 Variants
Greta Mastrangelo¹, Ellen Go², Paul Tsoukas², Hua Lu³, Amy Xu², Arthur Hoi Hin Cheng² and Rae Yeung⁴, ¹The Hospital of Sick Children,Department of Paediatrics, University of Toronto, Division of Rheumatology, Toronto, ON, Canada, ²The Hospital of Sick Children, Department of Paediatrics, University of Toronto, Division of Rheumatology; Cell Biology Program, The Hospital for Sick Children Research Institute, Toronto, ON, Canada, ³The Hospital for Sick Children, Toronto, ON, Canada, ⁴The Hospital for Sick Children, University of Toronto, Toronto, ON, Canada
Background/Purpose: Multisystem Inflammatory Syndrome in Children (MIS-C) is a serious complication associated with COVID-19, presenting as a hyperinflammatory disorder characterized by fever and multiorgan dysfunction.…
Abstract Number: 045 • 2023 Pediatric Rheumatology Symposium
Patient Reported Outcomes in Pediatric Vasculitis
Clare Peckenpaugh¹, Aimee Hersh², CJ Inman¹, Sara Stern¹, Erin Treemarcki², Peter Merkel³ and Karen James¹, ¹University of Utah Department of Pediatrics, Salt Lake City, UT, ²University of Utah, Salt Lake City, UT, ³University of Pennsylvania, Philidelphia, PA
Background/Purpose: Vasculitis is a group of multisystem, often relapsing diseases that can affect patients through disease activity, damage, and treatment toxicity. Vasculitis in adults often…
Abstract Number: 060 • 2023 Pediatric Rheumatology Symposium
Are the Levels of Cytokines Good Biomarkers for Smoldering Disease Activity in Childhood-Takayasu Arteritis?
Gleice Clemente¹, Maria Teresa Terreri², Bruno Gualano³, Clovis Silva⁴ and Alexandre Wagner De Souza¹, ¹Universidade Federal de São Paulo, São Paulo, Brazil, ²UNIFESP, São Paulo, Brazil, ³Universidade de São Paulo, São Paulo, ⁴Universidade de São Paulo, São Paulo, Brazil
Background/Purpose: Biomarkers for disease activity in adult Takayasu arteritis (TA) have been studied exhaustively, but there are inconsistencies among the studies (1). Childhood-TA (c-TA) differs…
Abstract Number: 061 • 2023 Pediatric Rheumatology Symposium
Variation in Treatment Approaches to IVIG- Refractory Kawasaki Disease (KD) Among Pediatric Rheumatologists: The Childhood Arthritis and Rheumatology Research Alliance (CARRA) Treatment of Refractory KD Survey
Daniel Ibanez¹, Bianca Lang², Ali Yalcindag³, Linda Wagner-Weiner⁴, Julia Shalen⁵, Kenneth Schikler⁶, Shoghik Akoghlanian⁷, Hulya Bukulmez⁸, Kristen Hayward⁹, Sivia Lapidus¹⁰, Andrea Ramirez¹¹, Robert Sundel¹, Cagri Yildirim-Toruner¹² and CARRA Registry Investigators¹³, ¹Boston Children's Hospital, Boston, MA, ²Dalhousie University - Halifax, Halifax, NS, Canada, ³Hasbro Children's Hospital, Milton, MA, ⁴The University of Chicago, Chicago, IL, ⁵Johns Hopkins University, Baltimore, MD, ⁶University of Louisville School of Medicine Norton Children's Hospital, Louisville, KY, ⁷Nationwide Children's Hospital, Columbus, OH, ⁸MetroHealth Medical Center, Case Western Reserve, Cleveland, OH, ⁹Seattle Children's Hospital/University of Washington School of Medicine, Seattle, WA, ¹⁰Department of Pediatrics, Joseph M. Sanzari Children's Hospital, Hackensack University Medical Center, Hackensack, NJ, ¹¹Baylor College of Medicine, Houston, TX, ¹²Baylor College of Medicine, Texas Children's Hospital, Houston, TX, ¹³CARRA, Washington, DC
Background/Purpose: Kawasaki disease (KD) is the leading cause of acquired heart disease in children in North America. Initial treatment with IVIG has significantly reduced the…
Abstract Number: 071 • 2023 Pediatric Rheumatology Symposium
Clinical Manifestations and Management of Takayasu Arteritis: A Single Center Pediatric Cohort
Ana Luiza Altaffer¹, Alvaro Orjuela² and Marietta De Guzman², ¹Texas Children's Hospital, Houston, TX, ²Baylor College of Medicine, Texas Children's Hospital, Houston, TX
Background/Purpose: Takayasu arteritis (TA) is a rare granulomatous vasculitis that affects large vessels, including the aorta, its major branches, and the pulmonary artery. Data on…
Abstract Number: L17 • ACR Convergence 2022
Evaluating the Safety and Factors Associated with Treatment Cessation in Takayasu Arteritis
Robert Maughan¹, Andrew Porter¹, Chanaka Dahanayake², Claudia Ianonne¹, Ritu Alapat¹, Charis Pericleous¹, Taryn Youngstein³ and Justin Mason¹, ¹Imperial College London, London, United Kingdom, ²Barts Health NHS Trust, London, United Kingdom, ³Imperial NHS Trust, London, United Kingdom
Background/Purpose: Immunosuppression in Takayasu Arteritis (TA) reduces the risk of arterial damage and disease progression. However, long-term use of glucocorticoids (GC) and other immunosuppressants carries…
Abstract Number: 0447 • ACR Convergence 2022
Is Systemic Vasculitis a Risk Factor for Myocardial Infarction? A Retrospective Cohort Study from the National Inpatient Sample
Kavin Raj¹, Marlene Marte Furment², Jyoti Verma³ and Keerthana Jyotheeswara Pillai⁴, ¹University of California Riverside School of Medicine, Riverside, CA, ²SUNY Upstate University Hospital, Syracuse, NY, ³Saint Peter's University Hospital, New Brunswick, NJ, ⁴Kilpauk Medical College, Chennai, India, New Brunswick, NJ
Background/Purpose: Systemic vasculitis is a group of uncommon conditions characterized by inflammation of blood vessels, leading to organ ischemia and necrosis. Although several rheumatological disorders…
Abstract Number: 0481 • ACR Convergence 2022
Glucocorticoid-related Adverse Events in Giant Cell Arteritis: Application of the Glucocorticoid Toxicity Index in a Monocentric Cohort of 140 Patients
Francesca Regola¹, Jacopo Mora¹, Giovanni Bosio², Laura Andreoli¹, Franco Franceschini¹ and Paola Toniati¹, ¹Rheumatology and Clinical Immunology Unit, ASST Spedali Civili and University of Brescia, Brescia, Italy, ²Nuclear Medicine Unit, ASST Spedali Civili of Brescia, Brescia, Italy
Background/Purpose: Oral glucocorticoids (GC) are the mainstay of treatment for giant cell arteritis (GCA) but chronic exposure to GC is associated with serious comorbidities. The…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].